Update on management of atrial fibrillation in heart failure: a focus on ablation

Bart A Mulder, Michiel Rienstra, Isabelle C Van Gelder, Yuri Blauuw

ABSTRACT

Atrial fibrillation (AF) and heart failure (HF) frequently coexist and influence progression of the other. A common adopted concept is that AF begets HF and HF begets AF due to shared pathophysiological mechanisms and risk factors. The combination of these diseases may subsequently increase the risk of stroke, dementia, HF hospitalisation and all-cause mortality. Early interventions are suggested to halt the progress of both diseases and improve prognosis. Recent European Society of Cardiology AF guidelines suggest that treatment of underlying conditions is pivotal and treatment should have a holistic approach (figure 1). Therefore, identification and treatment of risk factors should be key elements in AF treatment. This is even more of importance in patients with HF as AF negatively influences prognosis. In patients with HF, AF treatment options are limited; most antiarrhythmic drugs (AADs) are contraindicated or poorly tolerated. Amiodarone is effective but there is hesitance to use it, especially in young patients due to side-effects. Early targeted therapy of underlying conditions and risk factors in early persistent AF and moderately stable HF has been shown to improve sinus rhythm maintenance at 1 year. Also, long-term sustained weight loss in combination with optimal therapy of underlying heart diseases and risk factors is associated with significant reduction of AF burden and maintenance of long-term sinus rhythm, although these patients had no HF. Focus of AF rhythm control therapy has shifted towards catheter ablation. Several studies have shown that pulmonary vein isolation (PVI) with or without additional left atrial ablation may improve outcomes. Therefore, in this review, we evaluate the current treatment of AF in patients with HF, both with preserved (HFpEF) and reduced ejection fraction (HFrEF).

AF and HF

AF and HF are two entities which clinically may present alone but often are encountered together. AF and HF share many risk factors such as hypertension, obesity, diabetes mellitus and ischaemic heart disease. Due to these comorbidities and AF itself, an ‘atrial cardiomyopathy’ can develop as a consequence of the structural, architectural, contractile and electrophysiological changes that occur in the atria. The development of AF or HF first is of interest as the chronology of the diseases may impact prognosis. HF first seems to infer an inferior prognosis. AF, on the other hand, may contribute to the development of HF by several mechanisms. During AF, loss of atrial systole reduces left ventricular (LV) filling and may reduce cardiac output by 25%. Also, the irregularity and a too high heart rate during AF may increase the likelihood to develop LV dysfunction even leading to a reversible form of (tachy)cardiomyopathy. This is illustrated in patients who develop LV dysfunction during AF and show a recovery of LV ejection fraction (LVEF) after restoration of sinus rhythm. Thus, AF is of importance in the development and maintenance of LV dysfunction and, therefore, should be taken into account for every patient presenting with HF.

Clinical presentation of AF in HF

Key elements in diagnosing HF are signs and symptoms of HF and reduced LVEF. It, however, is often difficult to diagnose HFpEF in patients with AF. This is due to a large overlap in signs and symptoms. For example, breathlessness and fatigue are important symptoms in HF but may also be found in AF without diagnosed or recognised HF. A recent white paper suggested some signs and investigations to use in clinical practice.

AF treatment in the setting of HF

Pharmacological rhythm control is especially difficult in patients with HFrEF. Most AADs cannot be instituted because of their negative inotropic effects. Amiodarone is the only AAD approved for HFrEF but is unfortunately associated with many
adverse effects. Therefore, rate versus rhythm strategies were performed to assess whether there was any benefit for rhythm control. Noteworthy, these trials were performed before the era of ablation. The largest trial that studied rate versus rhythm control trial in patients with HF, the AF and congestive heart failure (AF-CHF) trial, included 1376 patients with LVEF of 35% or lower and randomised to a rate or pharmacological rhythm control strategy. No differences were observed in all-cause mortality or secondary outcomes (death from any cause, worsening HF or stroke).

In the recent Routine vs Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial included...

---

**Table 1** Overview of rate versus rhythm analysis investigating atrial fibrillation (AF) treatment in the setting of heart failure (HF) before the ablation era

<table>
<thead>
<tr>
<th>Study</th>
<th>No of patients</th>
<th>Mean age</th>
<th>Women</th>
<th>Persistent AF</th>
<th>Inclusion criteria</th>
<th>Endpoint</th>
<th>Comparison</th>
<th>Comorbidity treatment</th>
<th>Follow-up (years)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate versus rhythm trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIAMOND-CHF</td>
<td>1518</td>
<td>70</td>
<td>26.6%</td>
<td>100%</td>
<td>NYHA III/IV and LVEF &lt;35%</td>
<td>Mortality</td>
<td>Dofetilide versus placebo</td>
<td>0%</td>
<td>Not specified</td>
<td>1.5</td>
</tr>
<tr>
<td>RACE-HF</td>
<td>261</td>
<td>69</td>
<td>35%</td>
<td>100%</td>
<td>NYHA II/III</td>
<td>Composite of mortality and hospitalisation</td>
<td>Rate versus rhythm</td>
<td>0%</td>
<td>Not specified</td>
<td>2.3</td>
</tr>
<tr>
<td>AFFIRM-HF</td>
<td>788</td>
<td>N/A</td>
<td>25%</td>
<td>Recurrent AF</td>
<td>LVEF &lt;50%</td>
<td>ACM</td>
<td>Rate versus rhythm</td>
<td>0%</td>
<td>Not specified</td>
<td>3.5</td>
</tr>
<tr>
<td>AF-CHF</td>
<td>1376</td>
<td>67</td>
<td>18%</td>
<td>68.5%</td>
<td>LVEF &lt;35%</td>
<td>Cardiovascular death</td>
<td>Rate versus rhythm</td>
<td>0%</td>
<td>Not specified</td>
<td>3.1</td>
</tr>
<tr>
<td>CAFÉ-II</td>
<td>61</td>
<td>72</td>
<td>16%</td>
<td>100%</td>
<td>NYHA all and systolic dysfunction</td>
<td>QOL</td>
<td>Rate versus rhythm</td>
<td>0%</td>
<td>Not specified</td>
<td>1.0</td>
</tr>
</tbody>
</table>

ACM, all-cause mortality; LV(EF), left ventricular (ejection fraction); N/A, not available; NYHA, New York Heart Association; PVI, pulmonary vein isolation; QOL, quality of life.
In the field of catheter ablation in HF, several trials have been conducted. Important to note is that initial series were often single-centre studies that included a limited number of patients (41–81 patients) with limited follow-up (6–12 months) and had surrogate outcomes such as improvement in LVEF or exercise tolerance (table 2, figure 2). More recently, larger trials with substantial longer duration of follow-up and cardiovascular endpoints as well as sinus rhythm maintenance have been conducted. The Pulmonary vein antrum isolation vs AV node ablation with Bi-ventricular pacing for treatment of Atrial fibrillation in patients with Congestive Heart Failure (PABA-CHF) was among the first trials to investigate the efficacy of PVI in patients with HF. PABA-CHF compared the most definitive approach to achieve rate control, atrioventricular node ablation, with PVI. After 6 months of follow-up, the composite endpoint was in favour of PVI. Several small trials compared PVI with pharmacological rate control. A small study with only 41 patients compared PVI versus rate control (if heart rate was above 80 beats/min, digoxin was added) with change in LVEF as the primary endpoint. The study was underpowered to detect any difference in the LVEF change. Two other trials compared PVI with pharmacological rate control. Both were small studies (52 and 50

| Study | No of patients | Mean age | Women | Inclusion criteria | Endpoint | Comparison | PVI versus AVN ablation | PVI versus rate control (digoxin) | PVI versus rate control | PVI versus amiodarone | Sinus rhythm on 7-day Holter | Composite of death from CV causes, stroke, hospitalisation for HF or ACS | Early rhythm control or usual care (initial rate control, in case of symptoms mitigation to rhythm control) | Targeted therapy of underlying conditions versus conventional (causal treatment of AF and HF+symptom control) | Targeted therapy | Targeted therapy | Targeted therapy | Targeted therapy |
|-------|----------------|----------|-------|-------------------|----------|------------|-------------------------|-----------------------------------|--------------------------|----------------------|------------------------|--------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------|------------------|------------------|------------------|------------------|
| RACE 3 | 245            | 64       | 21%   | HFpEF=NYHA I–III and LVEF <45% | Sinus rhythm on 7-day Holter | Targeted therapy | N/A | Targeted therapy | 1.0 | Targeted therapy was superior (p=0.042) at 1 year; no differences at 5 years |
| EAST-AFNET | 2789        | 70       | 46%   | Stable heart failure (n=798 (28.6%)) | Composite of death from CV causes, stroke, hospitalisation for HF or ACS | Early rhythm control or usual care (initial rate control, in case of symptoms mitigation to rhythm control) | 13% | According to guidelines | 5.1 | Early rhythm control was superior (p=0.005) |

*No subgroup data available yet.

ACM, all-cause mortality; ACS, acute coronary syndrome; AVN, AV nodal ablation; CA, cardiac arrest; CV, cardiovascular; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; LVEF, left ventricular ejection fraction; 6-MWT, 6-minute walk test; N/A, not available; NYHA, New York Heart Association; PVI, pulmonary vein isolation; QOL, quality of life.
patients) and had limited follow-up (12 and 6 months, respectively). One showed that PVI was superior in increasing peak oxygen consumption after 12 months. The other trial showed a significant improvement in LVEF after 6 months of follow-up (table 2). Another recent small study included 68 patients and change in LVEF on repeat cardiac magnetic resonance (CMR) was the primary endpoint. Patients were randomised to either PVI or pharmacological rate control. After 6 months of follow-up, an improvement of LVEF was observed in those randomised to PVI. Of interest, restoration of sinus rhythm with PVI resulted in less fibrosis on CMR at 6 months as compared with rate control. These studies were pooled in several meta-analyses. These meta-analyses showed that AF ablation was associated with improved all-cause mortality, exercise capacity and LV systolic function. Average LVEF improvement ranged between 11% and 13% illustrating the advantage of AF ablation. Improvement in LVEF was most pronounced in patients with non-ischaemic cardiomyopathy. The beneficial effects of catheter ablation on LVEF and 6-minute walk test were not observed in the very small randomised trial performed by MacDonald et al. In another trial, almost 90% of patients had New York Heart Association (NYHA) III HF as a sign of advanced disease with probably more severe atrial cardiomyopathy, prohibiting catheter ablation to effectively restore and maintain sinus rhythm. A larger multicentre trial randomised 203 patients to either amiodarone or PVI (figure 2, table 2). After a follow-up of 24 months, freedom of AF was higher in those randomised to PVI (70% vs 34%). Furthermore, PVI was associated with a reduction of unplanned hospitalisation and mortality. The most relevant ablation trial in AF and HF, the Catheter Ablation vs Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF) trial, randomised 363 patients to either PVI or medical therapy (rate or rhythm control). Median LVEF was 25% (IQR 25%–38%, figure 2), 27% had cardiac resynchronisation therapy (CRT). PVI was associated with a significantly lower rate of the composite endpoint (28.5% vs 44.6%, p = 0.007), especially for the patients in the lower NYHA classes. Furthermore, an AF burden below 50% after 6 months of catheter ablation was associated with an improved outcome. Two other trials were performed in which also patients with HF were included. The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial randomised patients to either PVI or drug therapy (rate or rhythm control). This main trial results did not show that PVI was superior to drug therapy. Recently, the HF post-hoc analysis was published which did show an improved outcome in the PVI group (figure 2, table 2). Important to note is that the patients included in the CASTLE-AF and the post-hoc analysis of CABANA were different. In the CABANA analysis, only 9.3% of the patients had an LVEF <40% and the median LVEF was 55% implying a population with HFpEF rather than a population with HFrEF. The patients included in the CASTLE-AF had HFrEF (LVEF <35%) and a device (implantable cardioverter-defibrillator or CRT-D), whereas in CABANA HF was defined as NYHA functional class II or higher. This makes a direct comparison between these two trials challenging. Considering the difficulty of diagnosing HFpEF in the setting of AF, the question remains to what extent the CABANA-HF patients actually had HFpEF and not symptoms attributable to AF. The EAST-AFNET 4 trial randomised patients with and without HF to early rhythm control versus usual care. All patients had a short history of AF (<1 year), with one-third having their first episode of AF at inclusion. Notably, 1505 (53.9%) patients were in sinus rhythm at baseline. In the early rhythm control group, 20% underwent PVI and 46% started AAD during 2 years of follow-up. Patients randomised to early rhythm control had a lower risk of the primary outcome of death, stroke and hospitalisations (28.5% vs 44.6%). In EAST-AFNET 4, 28% of patients had stable HF (defined as NYHA functional class II or LVEF <50%). The post-hoc analysis of the patients with HF is not yet available.

**Implications**

The outcomes of these trials suggest that prolonged periods of sinus rhythm may result in improved LVEF, quality of life and prognosis in a selected group of patients with HF. Important to realise is that, for instance in CASTLE-AF, PVI had limited improvement.

---

**Table 2** Overview of catheter ablation studies in patients with heart failure (HF). AF, atrial fibrillation; AT, atrial tachycardia; CAD, coronary artery disease; CFAE, complex fragmented atrial electrograms; LVEF, left ventricular ejection fraction; PVI, pulmonary vein isolation.

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Median follow-up in months</th>
<th>AF ablation strategy</th>
<th>Ischaemic HF</th>
<th>LVEF</th>
<th>Persistent AF</th>
<th>Definition recurrence</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>PABA-CHF</td>
<td>81</td>
<td>6</td>
<td>PVI ± linear lines</td>
<td>73%</td>
<td>70%</td>
<td>51%</td>
<td>AF occurrence</td>
<td>2008</td>
</tr>
<tr>
<td>MacDonald</td>
<td>41</td>
<td>6</td>
<td>PVI ± linear lines</td>
<td>50%</td>
<td>33%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2011</td>
</tr>
<tr>
<td>ARC-HF</td>
<td>52</td>
<td>12</td>
<td>Step wise approach</td>
<td>26%</td>
<td>62%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2013</td>
</tr>
<tr>
<td>CAMTAF</td>
<td>50</td>
<td>12</td>
<td>PVI ± linear lines</td>
<td>32%</td>
<td>72%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2014</td>
</tr>
<tr>
<td>AATAC</td>
<td>203</td>
<td>24</td>
<td>PVI ± linear lines</td>
<td>29%</td>
<td>100%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2016</td>
</tr>
<tr>
<td>CAMERA-MRI</td>
<td>68</td>
<td>6</td>
<td>PVI ± linear lines</td>
<td>35%</td>
<td>72%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2017</td>
</tr>
<tr>
<td>CASTLE-AF</td>
<td>363</td>
<td>37</td>
<td>PVI ± linear lines</td>
<td>28%</td>
<td>70%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2018</td>
</tr>
<tr>
<td>CABANA-HF</td>
<td>778</td>
<td>48</td>
<td>PVI ± linear lines</td>
<td>22%</td>
<td>55%</td>
<td>100%</td>
<td>AF occurrence</td>
<td>2021</td>
</tr>
</tbody>
</table>

**Figure 2** Overview of catheter ablation studies in patients with heart failure (HF). AF, atrial fibrillation; AT, atrial tachycardia; CAD, coronary artery disease; CFAE, complex fragmented atrial electrograms; LVEF, left ventricular ejection fraction; PVI, pulmonary vein isolation.
success to maintain permanent long-term sinus rhythm. One of the proposed mechanisms behind the improvement in prognosis in the patients treated with PVI is that it significantly reduced total AF burden as is shown in figure 3.14 Post-hoc analysis showed that the risk for the primary endpoint was directly related to a low (<50%) or high (>50%) AF burden at 6 months.37 Another potential explanation is that part of the patients had a tachycardiomyopathy. Longer periods of sinus rhythm may, therefore, be a mechanism to improve outcome eventually. Although the results of these trials are of interest, one important limitation is to appreciate that HF is often not defined comparably (table results of these trials are of interest, one important limitation is to appreciate that HF is often not defined comparably (table 2).41 In the CASTLE-AF, an LVEF of <35% was considered HF; in the CABANA post-hoc analysis, an NYHA class of II or higher; and in EAST-AFNET 4, an LVEF <50% (or NYHA functional class II). This once again underlines the difficulty of diagnosing HF and interpreting results of these relevant trials. Future trials clearly warrant collaboration between electrophysiology and HF specialists.

Which ablation strategy to be used in patients with HF
PVI is considered the cornerstone of catheter ablation for AF, as no additional ablation options did show benefit so far.2 42 Moreover, in most trials, additional ablation (posterior wall isolation, linear lines or ablation of complex fractionated atrial electrograms) was up to the operator’s discretion and was not investigated in a randomised way. There are even less data available for patients with HF. This is illustrated by ablation strategies used in CASTLE-AF. Of the 151 patients randomised to the ablation group, a PVI-only approach was performed in 74 patients. In the other 77 patients, the first AF ablation was PVI with additional lines or ablation of atrial electrograms (figure 3).14 It illustrates that different strategies are still performed as primary PVI approach. Currently there are several trials enrolling patients with HF in whom a single-shot device is used implying a PVI-only approach. For example, the Cryoballoon Ablation vs Medical Therapy in Patients With Heart Failure and Atrial Fibrillation (RACE-8-HF, NCT04342832) and the Ablation of Atrial Fibrillation in Heart Failure patients (CONTRA-HF, NCT03062241) both use a cryoballoon as PVI approach as compared with medical therapy (non-specified, guideline directed). These results are highly anticipated as, in contrast to previous trials, a homogeneous initial PVI approach is used. Other key future PVI elements of interest is to create durable endocardial lesions. High-power short duration ablation is a technique where the procedure time is significantly decreased as the applications (point-by-point) have been shortened by using higher wattage for a shorter period of time (ie, 50 W for 5–15 s).31 44 The advantage of high-power short duration may be that extensive left atrial ablations addressing more advanced substrate in patients with HF will become more feasible. Long-term follow-up seems promising; however, these techniques should be investigated in large randomised HF trials.43 44 There are several surgical AF ablation strategies: thoracoscopic (minimally invasive using radiofrequency clamps onto the pulmonary veins), convergent (pericardioscopic epicardial posterior wall isolation) and hybrid ablation (combination of endocardial and epicardial ablation).2 45 Complications, however, should be taken into account for these more invasive procedures. Hybrid ablation strategies may improve outcome over single-staged surgical-only strategies, however, large randomised studies including patients with HF are definitely waited for.45–47 Clearly, future research endeavours should be performed into the field of high-power short duration, pulsed field ablation and hybrid/convergent AF ablation strategies in patients with AF and HF.

Patient selection
After addressing underlying cardiovascular conditions and treatment of risk factors, patients may be considered for catheter ablation according to the origin and severity of HF (figure 1).2 6 Presently, the number of patients with HF referred for catheter ablation is limited due to perceived higher complication rate and poor ablation outcome. Recent trials, however, demonstrate that AF ablation can be performed safely and long-term prognosis can improve, especially in patients with a tachycardiomyopathy, that is, without other demonstrable underlying heart disease. One of the main criticisms on the results of CASTLE-AF was that it was a selected population and therefore it is questionable

**Figure 3** Mean atrial fibrillation (AF) burden in CASTLE-AF. Pharmacological groups consist of pharmacological rate or rhythm control.
whether the beneficial effects will also be observed if AF ablation is performed at a larger scale.48 Yet, there are some patients’ characteristics which might guide whom will benefit from catheter ablation. Based on the post-hoc analysis of CASTLE-AF, patients with NYHA I/II and non-ischaemic aetiology of HF appear to benefit the most,36 suggesting that early intervention might be beneficial. Adding RACE 3 data to this observation, it may suggest even a better selection of patients that may benefit from ablation.49 When in doubt whether patients may benefit from sinus rhythm, a trial of cardioversion usually with a short period of amiodarone use can be attempted to evaluate whether sinus rhythm may lead to improvement of functional class and LVEF.50

CONCLUSIONS

Treatment of AF starts with optimal medical therapy of HF and other underlying cardiovascular diseases, as illustrated in figure 1.2 6 As demonstrated by recent large randomised trials (early), rhythm control including PVI may reduce AF burden in patients with HF and improve sinus rhythm maintenance, and also may have prognostic implications, especially in those with a tachycardiomyopathy. Research and treatment of AF in patients with HF should focus on implementing treatment of risk factors and comorbidities, improving selection of patients that may benefit from ablation and finally improving efficacy of ablation including more durable transmural lesions in an optimised lesion set. Preferably, those trials are performed by a team of electrophysiology and HF specialists. Ultimately this may lead to an improved individualised treatment strategy for patients with AF and HF.

REFERENCES


Twitter Bart A Mulder @BA_Mulder

Contributors All authors contributed to the drafting of the manuscript and approved the final contents.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Bart A Mulder http://orcid.org/0000-0002-4411-3918

Isabelle C Van Gelder http://orcid.org/0000-0002-7579-1201


© 2021 Heart Faculty. Produced by BMJ Publishing Group Ltd on behalf of the British Cardiovascular Society. All rights reserved.

Heart: first published as 10.1136/heartjnl-2020-318081 on 4 June 2021. Downloaded from http://heart.bmj.com/ on September 28, 2021 by guest. Protected by copyright.


